Clinical trial · Observational
Analysis of the Role of IgE Proteoforms in Health and Disease
NCT07328178CI-TRIAL-00100508IgE-PhDrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to evaluate the role of IgE proteoforms in healthy volunteers and in patients with type I allergy, patients with chronic spontaneous urticaria, patients with a recent history of anaphylaxis, patients with mastocytosis, patients with hereditary alpha tryptasemia, patients with X-linked agammaglobulinemia (XLA), and patients undergoing desensitization for venom or medication allergy.
Conditions
Conditions (9)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anaphylaxis | — | UNRESOLVED | — |
| Chronic Spontaneous Urticaria (CSU) | — | UNRESOLVED | — |
| Healthy Control | — | UNRESOLVED | — |
| Hereditary Alpha-Tryptasemia | — | UNRESOLVED | — |
| Mastocytosis | Mastocytosis | ONTOLOGY_EXACT | 0.98 |
| Medication Allergy | — | UNRESOLVED | — |
| Type I Allergy | — | UNRESOLVED | — |
| Venom Allergy | — | UNRESOLVED | — |
| X-linked Agammaglobulinaemia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (9)
- label
- Healthy controls
- interventionNames
- Other: Blood sample collection
- label
- Patients with type I allergy
- description
- Including medication allergy, venom allergy, food allergy, allergic rhinitis
- interventionNames
- Other: Blood sample collection
- label
- Patients with chronic spontaneous urticaria
- description
- With or without omalizumab
- interventionNames
- Other: Blood sample collection
- label
- Patients with a recent history of anaphylaxis
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * CSU and type I allergic diseases (including anaphylaxis and desensitization), atopic dermatitis, mastocytosis, XLA and HaT (informed consent, age: any available adult subject, gender: any available subject, clinical phenotype and specific information about the allergy (e.g. severity, medication, medical history, laboratory testing) * Healthy controls (informed consent, age matched to the allergic patients, gender matched to the allergic patients, patient-reported symptoms related to allergy to aeroallergens, food, drugs, hymenoptera venom, CSU) Exclusion Criteria: * Absence of informed consent * Age \< 18 years old
References
Publications (0)
Data not yet available
No reference posted for this study.